{
  "functional_evidence_assessment": [
    {
      "variant_string_id": "LRRK2 G2019S",
      "gene": "LRRK2",
      "protein_change": "G2019S",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "The study demonstrates that LRRK2 mutations (G2019S, Y1699C, G2385R) lead to dopaminergic neuron loss, locomotion deficits, reduced lifespan, and rotenone sensitivity, all consistent with Parkinsonism pathogenesis."
        },
        {
          "step": "Step 2: Evaluate the assay class",
          "details": "Transgenic Drosophila overexpression of LRRK2 variants (including wild-type) is used as a model organism, which is a standard approach for studying human disease mechanisms."
        },
        {
          "step": "Step 3: Validity of the assay",
          "details": "Wild-type LRRK2 is used as a control, and mutant variants show pathogenic effects. The study includes multiple experimental observations (neuron loss, locomotion deficits, rotenone sensitivity) without explicit mention of replicates, but the model organism approach is accepted in the field."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "No statistical tests or OddsPath values are explicitly reported. The study uses wild-type as a control (benign variant) and mutant variants as positive controls, with a total of 1 benign control. Since total controls <10, the evidence is classified as Max PS3_supporting."
        }
      ],
      "evidence_strength": "PS3_supporting",
      "conclusion": "Functional evidence supports pathogenicity of LRRK2 G2019S in Parkinsonism."
    },
    {
      "variant_string_id": "LRRK2 Y1699C",
      "gene": "LRRK2",
      "protein_change": "Y1699C",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "Y1699C variants show similar pathogenic effects as G2019S, including dopaminergic neuron loss and rotenone sensitivity, aligning with the disease mechanism described in the study."
        },
        {
          "step": "Step 2: Evaluate the assay class",
          "details": "Same transgenic Drosophila model as G2019S, with no mention of alternative assay methods."
        },
        {
          "step": "Step 3: Validity of the assay",
          "details": "Wild-type control is used, and Y1699C variants show pathogenic effects. The study includes multiple experimental observations, though replicates are not explicitly stated."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "No statistical tests or OddsPath values are explicitly reported. The study uses wild-type as a control (benign variant) and mutant variants as positive controls, with a total of 1 benign control. Since total controls <10, the evidence is classified as Max PS3_supporting."
        }
      ],
      "evidence_strength": "PS3_supporting",
      "conclusion": "Functional evidence supports pathogenicity of LRRK2 Y1699C in Parkinsonism."
    },
    {
      "variant_string_id": "LRRK2 G2385R",
      "gene": "LRRK2",
      "protein_change": "G2385R",
      "steps": [
        {
          "step": "Step 1: Define the disease mechanism",
          "details": "G2385R variants show similar pathogenic effects as G2019S, including dopaminergic neuron loss and rotenone sensitivity, consistent with the disease mechanism described in the study."
        },
        {
          "step": "Step 2: Evaluate the assay class",
          "details": "Same transgenic Drosophila model as G2019S and Y1699C, with no mention of alternative assay methods."
        },
        {
          "step": "Step 3: Validity of the assay",
          "details": "Wild-type control is used, and G2385R variants show pathogenic effects. The study includes multiple experimental observations, though replicates are not explicitly stated."
        },
        {
          "step": "Step 4: Apply evidence to individual variant interpretation",
          "details": "No statistical tests or OddsPath values are explicitly reported. The study uses wild-type as a control (benign variant) and mutant variants as positive controls, with a total of 1 benign control. Since total controls <10, the evidence is classified as Max PS3_supporting."
        }
      ],
      "evidence_strength": "PS3_supporting",
      "conclusion": "Functional evidence supports pathogenicity of LRRK2 G2385R in Parkinsonism."
    }
  ]
}